抗体偶联药物治疗腮腺导管腺癌一例及文献复习
南通市肿瘤医院/南通大学附属肿瘤医院, 放疗科, 江苏南通 226361
| 摘 要： | 涎腺导管癌（salivary ductal carcinoma, SDC）是一种罕见的高侵袭性恶性肿瘤，具有独特的病理和临床特征，它的组织学特征与乳腺导管癌高度相似。SDC的标准治疗方法是手术联合放疗，但发现时常病期较晚，预后较差。人生长因子受体2（HER2）过表达在SDC中比较常见，且HER2阳性SDC病例 具有较强的侵袭力，术后复发或转移患者的标准治疗方案，目前仍存在争议。维迪西妥单抗是我国自主研发的创新抗体偶联药物 ，以肿瘤表面的HER2蛋白为靶点，能精准识别和杀伤肿瘤细胞。本案例报道了1例维迪西妥单抗单药治疗HER2阳性SDC，起效迅速，疗效显著，可能是治疗该病的一个有前景的研究方向，但需进一步扩大样本量对照研究。 |
| 关 键 词： | 涎腺导管癌; 人生长因子受体2; 抗体偶联药物; 药物治疗 |
| DOI： | 10.57237/j.cmf.2022.01.004 |
View:
Downloads:
收稿日期: 2022-10-30
接受日期: 2022-12-01
在线出版日期: 2022-12-15
A Case Report and Literature Review of Antibody Conjugated Drugs for Parotid Ductal Adenocarcinoma
Department of Radiotherapy, Nantong City Tumor Hospital / Nantong University Cancer Hospital, Nantong 226361, China
| Abstract: | Salivary ductal carcinoma (SDC) is a rare highly aggressive malignancy with unique pathological and clinical features, and its histological features are highly similar to that of breast ductal carcinoma. The standard treatment for SDC is surgery plus radiation therapy, but it is often detected late and has a poor prognosis. Human growth factor receptor 2 (HER2) overexpression is common in SDC, and HER2-positive SDC cases have strong aggressiveness, and the standard treatment regimen for patients with postoperative recurrence or metastasis is still controversial. Vedicitumab is an innovative antibody coupling drug independently developed in China. It targets HER2 protein on the tumor surface and can accurately identify and kill tumor cells. This case reports a case of HER2 positive SDC treated with vidiximab alone, which has a rapid onset and significant effect. It may be a promising research direction for the treatment of this disease, but the sample size control study needs to be further expanded. |
| Keywords: | Salivary Duct Carcinoma; Human Growth Factor Receptor 2; Antibody-drug Conjugate; Drug Therapy |
参考文献
| [1] | Kleinsasser O, Klein HJ, HübnerG. Salivary duct carcinoma. A group of salivary gland tumors analogous to mammary duct carcinoma [J]. Arch Klin Exp Ohren Nasen Kehlkopfheilkd, 1968, 192 (1): 100-105. |
| [2] | Seifert G, Brocheriou C, Cardesa A, et al. WHO international histological classification of tumours. tentative histological classification of salivary gland tumours [J]. Pathol Res Pract, 1990, 186 (5): 555-581. DOI: 10.1016/S0344-0338(11)80220-7. |
| [3] | Boon E, Bel M, van Boxtel W, et al. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands [J]. Int J Cancer, 2018, 143 (4): 758-766. DOI: 10.1002/ijc.31353. Epub 2018 Mar 23. |
| [4] | Airoldi M, Garzaro M, Pedani F, et al. Cisplatin+vinorelbine treatment of recurrent or metastatic salivary gland malignancies (RMSGM): a final report on 60 cases [J]. Am J Clin Oncol, 2017, 40 (1): 86-90. DOI: 10.1097/COC.0000000000000112. |
| [5] | Dalin MG, Desrichard A, Katabi N, et al. Comprehensive molecular characterization of salivary duct carcinoma reveals actionable targets and similarity to apocrine breast cancer [J]. Clin Cancer Res, 2016, 22 (18): 4623-4633. DOI: 10.1158/1078-0432.CCR-16-0637. |
| [6] | Chen FJ, Jiang MX, Shao GL. et al. CT imaging findings and clinicopathological features of 16 cases with salivary duct carcinoma in parotid gland [J]. J Chin Oncol, 2015, 21 (5) 436-439. DOI: 10.11735/j.issn.1671-170X.2015.05.B019. |
| [7] | Castellano I, Allia E, Accortanzo V, et al. Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers [J]. Breast Cancer Res Treat, 2010, 124 (3): 607-617. DOI: 10.1007/s10549-010-0761-y. |
| [8] | Di Palma S, Simpson RH, Marchiò C, et al. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes [J]. Histopathology, 2012, 61 (4): 629-643. DOI: 10.1111/j.1365-2559.2012.04252.x. |
| [9] | Schmitt NC, Kang H, Sharma A. Salivary duct carcinoma: an aggressive salivary gland malignancy with opportunities for targeted therapy [J]. Oral Oncol, 2017, 74: 40-48. DOI: 10.1016/j.oraloncology.2017.09.008. |
| [10] | Luk PP, Weston JD, YuB, et al. Salivary duct carcinoma: clinicopathologic features, morphologic spectrum, and somatic mutations [J]. Head Neck, 2016, 38 (Suppl 1): E1838-E1847. DOI: 10.1002/hed.24332. |
| [11] | Skálová A, Stenman G, Simpson R, et al. The role of molecular testing in the differential diagnosis of salivary gland carcinomas [J]. Am J SurgPathol, 2018, 42 (2): e11-e27. DOI: 10.1097/PAS.0000000000000980. |
| [12] | JaehneM, RoeserK, JaekelT, et al. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases [J]. Cancer, 2005, 103 (12): 2526-2533. DOI: 10.1002/cncr.21116. |
| [13] | KHONGORZUL P, LING C J, KHAN F U, et al. AntibodyDrug Conjugates: A Comprehensive Review [J]. Mol Cancer Res, 2020, 18 (1): 3-19. |
| [14] | RICCIUTI B, LAMBERTI G, ANDRINI E, et al. Antibodydrug conjugates for lung cancer in the era of personalized oncology [J]. Semin Cancer Biol, 2019, 30:S1044-579X (19): 30424-30429. |
| [15] | Xu Y, Wang Y, Gong J, et al. Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors. Gastric Cancer 2021; 24: 913-25. |
